Acute Myelogenous Leukemia

Oncology·MeSH: Leukemia, Myeloid, Acute

Prevalence

30.0 / 100K

26 drugs in development·9 companies·11 clinical trials

Drug Pipeline by Phase

Phase 2(17)

Drug	Company
conditioning regimen a	HWH International Inc. (HWH)
conditioning regimen b	HWH International Inc. (HWH)
conditioning regimen c	HWH International Inc. (HWH)
conditioning regimen d	HWH International Inc. (HWH)
conditioning regimen e	HWH International Inc. (HWH)
Cytarabine	AbbVie Inc. (ABBV)
emavusertib	CURIS INC (CRIS)
Emavusertib (CA-4948)	CURIS INC (CRIS)
Glasdegib	Jazz Pharmaceuticals plc (JAZZ)
post-transplant abatacept	HWH International Inc. (HWH)
post-transplant mycophenolate mofetil	HWH International Inc. (HWH)
post-transplant tacrolimus	HWH International Inc. (HWH)
ptcy (25 mg/kg d3	HWH International Inc. (HWH)
ptcy (25 mg/kg d3	GH Research PLC (GHRS)
ptcy (50 mg/kg d3	GH Research PLC (GHRS)
ptcy (50 mg/kg d3	HWH International Inc. (HWH)
supportive care	HWH International Inc. (HWH)

Phase 1(4)

Drug	Company
ABT-199	AbbVie Inc. (ABBV)
MCLA-117 bispecific antibody	Merus N.V. (MRUS)
mipletamig	Aptevo Therapeutics Inc. (APVO)
Posaconazole	AbbVie Inc. (ABBV)

Preclinical(1)

Drug	Company
gtb-3550	GT Biopharma, Inc. (GTBP)

N/A(1)

Drug	Company
LILRB4 STAR-T cells injection	Filana Therapeutics Inc. (FLNA)

Phase 1/Phase 2(2)

Drug	Company
cd33cart allogeneic	HWH International Inc. (HWH)
cd33cart autologous	HWH International Inc. (HWH)

Phase 4(1)

Drug	Company
Infusion of HS-IT101 Injection	Filana Therapeutics Inc. (FLNA)

BioSniper tracks 26 drugs in development for Acute Myelogenous Leukemia across 9 companies.

There are 11 clinical trials targeting Acute Myelogenous Leukemia tracked by BioSniper.

The estimated prevalence of Acute Myelogenous Leukemia is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.